Effect of Exogenous Melatonin on Morphological Features of B16 Melanoma in Mice

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Constant illumination over a long period of time suppresses the hormone-synthesizing function of the pineal gland, leading to a decrease in melatonin levels and, consequently, to accelerated aging of the body, increased incidence of age-associated pathologies, including neoplasms, and shortened life expectancy. Melatonin has a pronounced antitumor effect. In particular, its antiproliferative effect is highlighted. Melanoma is one of the most malignant neoplasms in humans, originating from melanin-producing cells. In recent years, the proportion of older patients among patients with melanoma has been increasing, which makes it possible to classify this disease as age-associated. There is evidence that melatonin deficiency and the resulting disruption of the body’s circadian rhythms is one of the factors contributing to the development of melanoma.

AIM: To investigate the effect of exogenous melatonin on the morphological features of B16 melanoma in mice.

METHODS: The study was conducted on male hybrid mice of the BDF1 line (n = 60) at the age of 8 weeks, weighing 21–22 g. All animals received subcutaneous transplantation of B16/F10 melanoma in suspension. The mice were further divided into two groups, control and experimental. Animals of the experimental group were administered melatonin (Sigma, USA) at a dose of 5 mg/kg intragastrically from the first day of the study. On the 15th day after tumor transplantation, the tumor itself, as well as the lungs and liver, were removed. Pathomorphological examination of the tumor was performed, and the presence of lung and liver metastases was determined. Area of necrosis was measured on histological slides of the tumor stained with hematoxylin and eosin, and the nuclear-cytoplasmic ratio in tumor cells was calculated by measuring the cross-sectional area of nuclei and the cross-sectional area of cells. Graphing and statistical analysis of the results were performed using GraphPad Prism v8.41 (USA).

RESULTS: It was found that melatonin administration during the studied period reduced the mortality of mice with melanoma, decreased the incidence of tumor metastasis and tumor size. In addition, in melanomas of the experimental group of mice, signs of tumor regression in the form of foci of dystrophic and alterative changes were visualized, as well as a statistically significant increase in the area of tumor necrosis.

CONCLUSION: The present study showed that exogenous melatonin has a pronounced antitumor effect against B16 melanoma in mice. The obtained results allow planning more thorough and multidisciplinary studies for in-depth investigation of the mechanisms of melatonin antitumor effect.

Full Text

Restricted Access

About the authors

David A. Areshidze

Petrovsky National Research Centre of Surgery

Author for correspondence.
Email: labcelpat@mail.ru
ORCID iD: 0000-0003-3006-6281
SPIN-code: 4348-6781

Cand. Sci. (Biology)

Russian Federation, Moscow

Maxim V. Mnikhovich

Petrovsky National Research Centre of Surgery

Email: mnichmaxim@yandex.ru
ORCID iD: 0000-0001-7147-7912
SPIN-code: 6975-6677

Cand. Sci. (Medicine)

Russian Federation, Moscow

Roman V. Deev

Petrovsky National Research Centre of Surgery

Email: romdey@gmail.com
ORCID iD: 0000-0001-8389-3841
SPIN-code: 2957-1687

Cand. Sci. (Medicine), Associate Professor

Russian Federation, Moscow

Maria A. Kozlova

Petrovsky National Research Centre of Surgery

Email: ma.kozlova2021@outlook.com
ORCID iD: 0000-0001-6251-2560
SPIN-code: 5647-1372

Cand. Sci. (Biology)

Russian Federation, Moscow

Anna I. Anurkina

Petrovsky National Research Centre of Surgery

Email: anyaaai1925@gmail.com
ORCID iD: 0009-0003-0011-1114
SPIN-code: 9812-3412
Russian Federation, Moscow

Denis V. Mishchenko

Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences

Email: mdv@icp.ac.ru
ORCID iD: 0000-0003-3779-3211
SPIN-code: 4213-3318

Cand. Sci. (Biology)

Russian Federation, Chernogolovka

Tatyana Е. Sashenkova

Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences

Email: tsashen52@mail.ru
ORCID iD: 0000-0002-2753-979X
Russian Federation, Chernogolovka

Anton N. Turchin

Mechnikov North-Western State Medical University

Email: ktogrb@yandex.ru
ORCID iD: 0009-0008-5302-5769
Russian Federation, Saint Petersburg

References

  1. Anisimov VN. Light pollution, reproductive function and cancer risk. Neuro Endocrinol Lett. 2006;27(1–2):35–52.
  2. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8(12):1065–1066. doi: 10.1016/S1470-2045(07)70373-X
  3. Pauley SM. Lighting for the human circadian clock: recent research indicates that lighting has become a public health issue. Med Hypotheses. 2004;63(4):588–596. doi: 10.1016/j.mehy.2004.03.020
  4. Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009;38(4):963–970. doi: 10.1093/ije/dyp178
  5. Arushanian EB, Naumov SS. A wide range of pharmacological properties of melatonin. Reviews on Clinical Pharmacology and Drug Therapy. 2021;19(1):103–106. (In Russ.) doi: 10.17816/RCF191103-106 EDN: XKUIWB
  6. Sato K, Meng F, Francis H, et al. Melatonin and circadian rhythms in liver diseases: functional roles and potential therapies. J Pineal Res. 2020;68(3):e12639. doi: 10.1111/jpi.12639
  7. Zuev VA, Trifonov NI, Linkova NS, Kvetnaia TV. Melatonin as a molecular marker of age-related pathologies. Advances in Gerontology. 2017;30(1):62–69. (In Russ.) EDN: YHTMRF
  8. Anisimov VN, Vinogradova IA. Light regime, biorythms and organism aging. Aesthetic Medicine Bulletin. 2011;10(1):42–51. (In Russ.) EDN: OEVILV
  9. Anisimov VN. Light, aging, and cancer. Priroda. 2018;(6):19–22. (In Russ.) EDN: XQNOMP
  10. Kvetnaia TV, Polyakova VO, Proshaev KI, et al. Melatonin as a marker of ageing and age-associated diseases. RUDN Journal of Medicine. 2012;(S7):125–126. (In Russ.) EDN: RCADUR
  11. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351(2):152–166. doi: 10.1016/j.mce.2012.01.004
  12. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;85(3):335–353. doi: 10.1016/j.pneurobio.2008.04.001
  13. Malishevskaya NP, Sokolova AV, Demidov LV. The incidence of skin melanoma in the Russian Federation and federal districts. Medical Council. 2018;(10):161–165. (In Russ.) doi: 10.21518/2079-701X-2018-10-161-165 EDN: UUDAMY
  14. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46(2):270–283. doi: 10.1016/j.ejca.2009.10.032
  15. Erkenova FD, Puzin SN. Statistics of melanoma in Russia and Europe. Medical and Social Expert Evaluation and Rehabilitation. 2020;23(1):44–52. (In Russ.) doi: 10.17816/MSER34259 EDN: WIAAEF
  16. de Assis LVM, Moraes MN, Mendes D, et al. Loss of Melanopsin (OPN4) leads to a Faster cell cycle progression and growth in murine melanocytes. Curr Issues Mol Biol. 2021;43(3):1436-1450. doi: 10.3390/cimb43030101
  17. Lubov JE, Cvammen W, Kemp MG. The impact of the circadian clock on skin physiology and cancer development. Int J Mol Sci. 2021;22(11):6112. doi: 10.3390/ijms22116112
  18. Mubashshir M, Ahmad N, Sköld HN, Ovais M. An exclusive review of melatonin effects on mammalian melanocytes and melanoma. Exp Dermatol. 2023;32(4):324–330. doi: 10.1111/exd.14715
  19. Jansen R, Osterwalder U, Wang SQ, et al. Photoprotection: part II. Sunscreen: development, efficacy, and controversies. J Am Acad Dermatol. 2013;69(6):867.e1–14. doi: 10.1016/j.jaad.2013.08.022
  20. Slominski AT, Hardeland R, Zmijewski MA, et al. Melatonin: a cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol. 2018;138(3):490–499. doi: 10.1016/j.jid.2017.10.025
  21. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997–3025. doi: 10.1007/s00018-014-1579-2
  22. Alvarez-Artime A, Cernuda-Cernuda R, Francisco-Artime-Naveda, et al. Melatonin-induced cytoskeleton reorganization leads to inhibition of melanoma cancer cell proliferation. Int J Mol Sci 2020;21(2):548. doi: 10.3390/ijms21020548
  23. Cutando A, López-Valverde A, Arias-Santiago S, et al. Role of melatonin in cancer treatment. Anticancer Res. 2012;32(7):2747–2753.
  24. Treshchalina EM, Zhukova OS, Gerasimova GK, et al. Methodological recommendations for the preclinical study of the antitumor activity of drugs. In: Guidelines for conducting preclinical studies of drugs. Pt. 1. Moscow: Grif i K; 2012. P:640–656. (In Russ.)
  25. Broeke J, Pérez JMM, Pascau J. Image Processing with ImageJ. Birmingham: Packt Publishing; 2015.
  26. Franco PIR, do Carmo Neto JR, Milhomem AC, et al. Antitumor effect of melatonin on breast cancer in experimental models: a systematic review. Biochim Biophys Acta Rev Cancer. 2023;1878(1):188838. doi: 10.1016/j.bbcan.2022.188838
  27. Fathizadeh H, Mirzaei H, Asemi Z. Melatonin: an anti-tumor agent for osteosarcoma. Cancer Cell Int. 2019;19:319. doi: 10.1186/s12935-019-1044-2
  28. Shen D, Ju L, Zhou F, et al. The inhibitory effect of melatonin on human prostate cancer. Cell Commun Signal. 2021;19(1):34. doi: 10.1186/s12964-021-00723-0
  29. Su SC, Hsieh MJ, Yang WE, et al. Cancer metastasis: mechanisms of inhibition by melatonin. J Pineal Res. 2017;62(1). doi: 10.1111/jpi.12370
  30. Martínez-Campa C, Álvarez-García V, Alonso-González C, et al. Melatonin and its role in the epithelial-to-mesenchymal transition (EMT) in cancer. Cancers (Basel). 2024;16(5):956. doi: 10.3390/cancers16050956
  31. Lu KH, Lin CW, Hsieh YH, et al. New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence. Cancer Metastasis Rev. 2020;39(1):303–320. doi: 10.1007/s10555-020-09845-2
  32. Wang L, Wang C, Choi WS. Use of melatonin in cancer treatment: where are we? Int J Mol Sci. 2022;23(7):3779. doi: 10.3390/ijms23073779
  33. Blask DE, Dauchy RT, Sauer LA, Krause JA. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis. 2004;25(6):951–960. doi: 10.1093/carcin/bgh090
  34. Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49(3):271–282. doi: 10.1111/j.1600-079X.2010.00792.x

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Physical characteristics of mice: a, body weight (g); b, tumor weight (g); c, tumor volume (cm3); ***, p ≤ 0.0005 compared to the control group.

Download (88KB)
3. Fig. 2. Melanoma in mice of the control group: a, subcutaneous tumor node of epithelioid cell melanoma; b, areas of muscle infiltration with tumor cells in the projection of the tumor growth zone, necrosis with an area of leukocytic infiltration (black arrow), vascular wall with focal necrosis and focal lymphoplasmacytic infiltration (white arrow); c, a cell in the state of apoptosis in the thickness of the regressive part of the tumor (white arrow), focal perivascular infiltrate (black arrow). Hematoxylin and eosin staining, 200x magnification.

Download (474KB)
4. Fig. 3. Melanoma in mice of the experimental group: a, focus of necrosis (black arrow) surrounded by inflammatory cell cluster and interstitial edema (white arrow); b, regressive part of the tumor with dystrophic changes in tumor cells (black arrow), prominent lymphoplasmacytic infiltration and extensive zone of necrosis (white arrow); c, necrosis (black arrow) and apoptotic bodies in the tumor. Hematoxylin and eosin staining; magnification: a, b, 100x; c, 200x.

Download (482KB)
5. Fig. 4. Morphometric parameters of B16 melanoma cells in mice: a, nucleus cross-sectional area (μm2); b, cell cross-sectional area (μm2); c, nuclear-cytoplasmic ratio; **, p ≤ 0.005, ***, p ≤ 0.0005 when comparing two groups.

Download (100KB)

Copyright (c) 2025 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

Периодический печатный журнал зарегистрирован как СМИ Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор): 0110212 от 08.02.1993.
Сетевое издание зарегистрировано как СМИ Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор): ЭЛ № ФС 77 - 84733 от 10.02.2023.